177795-59-4

Basic information

• Product Name: (S)-Rabeprazole
• Synonyms: (S)-Rabeprazole;2-[(S)-[[4-(3-Methoxypropoxy)-3-Methyl-2-pyridinyl]Methyl]sulfinyl]-1H-benziMidazole
• CAS NO: 177795-59-4
• Molecular Formula: C18H21N3O3S
• Molecular Weight: 359.44264
• Product Categories: Chiral Reagents;Intermediates & Fine Chemicals;Pharmaceuticals
• Mol File: 177795-59-4.mol
• Article Data: 59

Chemical Properties

• Boiling Point: 603.9±65.0 °C(Predicted)
• Appearance: /
• Density: 1.33±0.1 g/cm3(Predicted)
• PKA: 9.57±0.10(Predicted)
• CAS DataBase Reference: (S)-Rabeprazole(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-Rabeprazole(177795-59-4)
• EPA Substance Registry System: (S)-Rabeprazole(177795-59-4)

Safety Data

• Hazardous Substances Data: 177795-59-4(Hazardous Substances Data)

Upstream product

• 117976-90-6 Rabeprazole sodium 
• 184713-27-7 1-Benzyloxymethyl-2-[4-(3-methoxy-propoxy)-3-methyl-pyridin-2-ylmethanesulfinyl]-1H-benzoimidazole 
• 117977-21-6 rabeprazole sulfide 
• 134469-07-1 Benzimidazol-2-thiol 
• 37699-43-7 2,3-dimethyl-4-nitropyridine N-oxide 
• 1589-49-7 methoxypropanol 
• 924663-40-1 2-[[(4-(3-methoxypropoxy)-3-methyl-pyridin-2-yl-1-oxide)methyl]sulfanyl]-1H-benzoimidazole 
• 408332-88-7 Diethyl tartrate 
• 13811-71-7 diethyl (2S,3S)-tartrate 
• 937-14-4 3-chloro-benzenecarboperoxoic acid 
• 924663-38-7 2-[[(RS)-(1H-benzimidazol-2-yl)sulfinyl]methyl]-4-(3-methoxypropoxy)-3-methylpyridine 1-oxide 
• 1080503-70-3 2,3-dimethyl-4-(3-methoxy-propoxy)pyridine 
• 1080503-68-9 (-)-menthyl 2-benzimidazolylsulphinate 
• 5038-11-9 N,N'-thiodimorpholine 

Downstream Products

• 259183-43-2 1-[[2-{2-(morpholin-4-yl)ethoxy}ethoxy]phenyl-4-sulfonyl]-2-[[[4-(3-methoxypropoxy)-3-methyl-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole 
• 924663-37-6 2-[(4-(3-methoxypropoxy)-3-methyl-pyridin-2-yl-1-oxide)methylsulfonyl]-1H-benzoimidazole 

Relevant articles and documents

Method for preparing chiral sulfoxide drugs in water phase

The invention relates to the field of chiral drug preparation, in particular to a method for preparing chiral sulfoxide drugs in a water phase. The method for preparing the chiral sulfoxide drugs in the water phase comprises the following steps: using a hydrogen peroxide solution as oxidant, using a temperature-sensitive ferrocene chiral amino acid titanium complex as a catalyst and using prochiral thioether as a substrate in the pure water phase to perform an asymmetric oxidation reaction to synthesize the chiral sulfoxide drugs. The temperature-sensitive ferrocene chiral amino acid titaniumcomplex catalyst can be utilized to catalyze the asymmetric oxidation reaction of thioether in the pure water phase and has the characteristics of high catalytic efficiency and easy recovery of the catalyst.

Rabeprazole analogue preparation method

The invention discloses a rabeprazole analogue preparation method, and particularly relates to a (R)-rabeprazole preparation method. According to the method, under the co-action of a vanadium metal and a tetradentate organic ligand, a prochiral thioether compound is oxidized with an oxidizing agent to generate (R)-rabeprazole. The method of the present invention has advantages of high enantioselectivity, high product purity and high yield, and is suitable for industrial production.

Method for preparing benzimidazole proton pump inhibitor

The invention provides a novel method for preparing a benzimidazole proton pump inhibitor, and belongs to the field of medicine synthesis. According to the method provided by the invention, a complexformed by using graphene oxide and a transition metal salt is used as a catalyst, and the corresponding benzimidazole proton pump inhibitor is obtained through oxidizing a thioether by an oxidizing agent under an alkaline condition in an organic solvent. The method has the advantages of mild reaction condition, high yield, environmental friendliness, and less impurity, the catalyst can be recycled, and the method is suitable for industrial production.